Association of prevalence of rhinitis, atopic eczema, rhinoconjunctivitis and wheezing with mortality from infectious diseases and with antibiotic susceptibility at a country level

Claudia Fsadni1,2,*, Peter Fsadni1,2, Stephen Fava1,2, and Stephen Montefort1,2

1Department of Medicine, Mater Dei Hospital, Msida, MSD 2090, Malta
2Faculty of Medicine and Surgery, University of Malta, Msida, MSD 2090, Malta

Background: It was previously reported that there is a positive correlation between incidence of type 1 diabetes and prevalence of asthma and atopic eczema. A negative correlation between the prevalence of type 1 diabetes and mortality from infectious diseases as well as a positive correlation with antibiotic susceptibility at a country level have also been reported.

Objective: The aim of this study was to investigate the association between country prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing with mortality from infectious diseases and also with antibiotic susceptibility at a country level.

Methods: Data for prevalence of rhinitis, eczema, rhinoconjunctivitis, and wheezing was obtained from the International Study of Asthma and Allergies in Childhood study (ISAAC). ISAAC Phase one was a multicentre multicountry cross sectional study involving over 700,000 children in 2 age groups of school children, 13–14 years old (adolescents) and 6–7 years old (children) in 156 centres from 56 countries. Mortality from infectious diseases was taken from World Health Organisation data. The Alexander project was used to identify antibiotic susceptibilities to common bacteria.

Results: There were significant positive correlations between atopic eczema and mortality from all infectious diseases studied, diarrhoeal illness, tropical infections, and childhood infections. A negative correlation exists between the prevalence of rhinitis and Streptococcus pneumoniae susceptibility to penicillin and to erythromycin, rhinitis and Haemophilus influenzae susceptibility to ampicillin and between rhinoconjunctivitis and H. influenzae susceptibility to ampicillin.

Conclusion: Th1/Th2 responses might influence the pathogenesis of infectious disease mortality, while antibiotic overprescription could explain the negative association between atopy and antibiotic susceptibility.

Key words: Rhinitis; Conjunctivitis, Allergic; Eczema; Asthma; Communicable Diseases; Anti-Infective Agents
INTRODUCTION

Atopic eczema is a chronic inflammatory skin condition that appears to be potentially associated with genetic and acquired defects in the proteins and lipids in the outer layer of the epidermis. This leads to a breakdown in the barrier between the internal body structures and the environment. Eczema is often linked to other atopic conditions including asthma and allergic rhinitis and rhinoconjunctivitis [1]. It affects approximately 5% to 20% of children worldwide [2] and the incidence appears to be on the increase. It appears to be higher in urban areas and developed countries, especially Western societies [3, 4].

Our group has previously reported a correlation between incidence of type 1 diabetes and prevalence of asthma and atopic eczema [5]. The ‘hygiene hypothesis’ proposes that lack of microbial exposure in early postnatal life predisposes to certain immune-mediated diseases. It has been implicated in the pathogenesis of both type 1 diabetes [6] as well as in the pathogenesis of atopic diseases such as atopic eczema and asthma [7]. Lack of microbial exposure may therefore explain the observed correlation between the incidence of type 1 diabetes and prevalence of atopic disease. It has been suggested that infectious disease mortality and antibiotic susceptibility may be good markers of infective burden at a population level [8]. We therefore sought to investigate the possible relationship between the country prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing as documented in the International Study of Asthma and Allergies in Childhood study (ISAAC). Phase one study [9] to mortality from infectious and parasitic diseases were included in the study. For countries with data both in the ISAAC phase 1 study and in the WHO database were included in the study. For countries with multiple centre data, the mean country prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing was taken.

WHO estimates of mortality and global burden of disease

The WHO estimates of mortality and burden of disease for member states for the year 2002 including country specific mortality and burden of disease for over 130 causes were reviewed. These estimates are based on version 3 of the Global Burden of Disease study [10] as published in the World Health Report 2004 [11]. Available data include age-standardised death rates quoted per 100,000 population by cause and member state. Mortality data is grouped into (1) mortality from communicable, maternal, perinatal and nutritional conditions, (2) mortality from noncommunicable diseases, and (3) mortality from injuries. Within the mortality from communicable, maternal, perinatal, and nutritional conditions group, there are specific mortality rates from infectious and parasitic diseases in general as well as that from respiratory infection, tuberculosis and diarrhoeal diseases.

The Alexander project

The Alexander project [12] was established in 1992 and is an ongoing surveillance project that examines the susceptibility of bacteria responsible for adult community-acquired respiratory tract infections to a range of antibiotics. Between 1998 and 2002, isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis were collected from centres in USA, Africa, Europe, the Far and Middle East, and Latin America and their susceptibility to 23 different antibiotics was tested.

Research design

Countries with data both in the ISAAC phase 1 study and in the WHO database were included in the study. For countries with multiple centre data, the mean country prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing was taken.

For countries which participated in the ISAAC study, the WHO country-specific age-standardised death rates (quoted per 100,000 inhabitants) from infectious and parasitic diseases were
Association of atopy with infectious disease mortality

documented. These infections included respiratory infections, tuberculosis and diarrhoeal illness among others. We decided to choose mortality data related to common childhood infections to be able to look at the relationship between these infections and prevalence of common atopic symptoms at a population level for each country.

The Alexander project was used to obtain data for antibiotic susceptibility. Country-specific antibiotic susceptibility data was available for 18 countries which participated in both the Alexander project (between 1998 and 2000) and the ISAAC phase I study. Country-specific antibiotic susceptibility data for *S. pneumoniae* and *H. influenzae* were available; these two organisms most commonly cause bacterial infections in childhood. We then proceeded to extract data for the four most important and commonly used antibiotics namely penicillin, erythromycin, doxycycline, and cotrimoxazole. Susceptibility of *S. pneumoniae* to penicillin and erythromycin was based on National Committee for Clinical Laboratory Standards breakpoints, while susceptibility of *S. Pneumoniae* to doxycycline and cotrimoxazole and susceptibility of *H. influenzae* to all antimicrobials were based on pharmacokinetic/pharmacolodynamic breakpoints [12]

Data analysis

Prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing and mortality from communicable diseases

Pearson correlation analyses of the country-specific prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing to the country-specific mortality from all cause infectious and parasitic diseases, tuberculosis, diarrhoeal illnesses, tropical infections, childhood infections and from respiratory infections were performed.

Prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing and antibiotic susceptibility

Pearson correlation analyses were also carried out between the atopic symptoms mentioned above and the country-specific susceptibility of *S. Pneumoniae* and *H. Influenzae* to the antibiotics listed earlier.

RESULTS

Prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing and mortality from infectious diseases and respiratory infections

The country-specific prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing and mortality from infectious diseases, respiratory infections, tuberculosis, diarrhoeal illnesses, tropical infections, and childhood illnesses are shown in Table 1. There was a significant positive correlation between atopic eczema and mortality from all infectious diseases studied (Fig 1) (\(r = 0.33, p = 0.013\)), diarrhoeal illnesses (\(r = 0.33, p = 0.014\)), tropical infections (\(r = 0.39, p = 0.003\)), and childhood illnesses (\(r = 0.35, p = 0.008\)). There was no significant correlation between the above conditions and the mortality from respiratory infections when these were isolated from other infections (Table 2).

Prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing and antibiotic susceptibility

The correlation between prevalence of rhinitis, atopic eczema, rhinoconjunctivitis, and wheezing and antibiotic susceptibility are shown in Table 3.

There were significant negative correlations between rhinitis and *S. pneumoniae* susceptibility to penicillin (\(r = -0.51, p = 0.029\)) (Fig 2) and erythromycin (\(r = -0.59, p = 0.010\)) (Fig 3). There were also significant negative correlations between rhinitis and *H. influenzae* susceptibility to ampicillin (\(r = -0.59, p = 0.010\)) (Fig 4) and between rhinoconjunctivitis and *H. influenzae* susceptibility to ampicillin (\(r = -0.51, p = 0.030\)) (Fig 5).

DISCUSSION

In our ecological study we found a significant positive correlation between the country prevalence of atopic eczema and the country’s mortality from infectious diseases. To our knowledge, this has not been previously reported. This relationship was true for total mortality from infectious diseases and parasitic infections (\(r = 0.33, p = 0.013\)) as well as to mortality from specific infections including diarrhoea (\(r = 0.33, p = 0.014\)), tropical infections (\(r = 0.39, p = 0.030\)), and childhood infections (\(r = 0.35, p = 0.008\)). There was a similar trend for mortality from respiratory infections but this did not reach statistical significance. Our data suggest that there may be common genetic and/or environmental factors which predispose to both atopic eczema and to the risk and/or severity of infections. These may include factors which predispose to a predilection of a Th2 over a Th1 response, which has been reported to have a genetic element [13]. Th2/Th11 predominance

apallergy.org http://dx.doi.org/10.5415/apallergy.2015.5.3.145
### Table 1. Country-specific prevalence of eczema, rhinitis, wheezing and rhinoconjunctivitis in the 13- to 14-year-old age group and age standardized disease mortality

| Country   | Atopic eczema | Rhinitis | Wheeze | Rhinoconjunctivitis | ID mortality | Respiratory infections mortality | TB mortality | Diarrhoea mortality | Tropical infections mortality | Childhood infections mortality |
|-----------|----------------|----------|--------|---------------------|--------------|---------------------------------|--------------|---------------------|-------------------------------|-------------------------------|
| Algeria   | 4.2            | 37.9     | 7.8    | 14.1                | 124.2        | 66.6                            | 2.3          | 24.3                | 3.3                           | 10.8                          |
| Ethiopia  | 11.6           | 16.4     | 6.3    | 6.2                 | 71.3         | 143.2                           | 90.3         | 66.1                | 31.8                          | 43.9                          |
| Kenya     | 10.4           | 18.3     | 13.8   | 12.1                | 872.3        | 127.4                           | 96.4         | 62.2                | 9.5                           | 9.1                           |
| S. Africa | 8.3            | 30.3     | 16.1   | 15.1                | 966.2        | 84.5                            | 37.4         | 29.1                | 0.1                           | 0.1                           |
| Nigeria   | 17.7           | 45.3     | 10.7   | 39.7                | 834.3        | 149.1                           | 91.5         | 84.7                | 25.7                          | 76.9                          |
| Tunisia   | 8.0            | 48.9     | 8.5    | 35.8                | 24.1         | 28.5                            | 3.0          | 76.6                | 0.1                           | 0.1                           |
| China     | 1.1            | 30.5     | 4.3    | 73                  | 43.1         | 29.4                            | 22.6         | 101                 | 0.3                           | 2.0                           |
| Japan     | 10.5           | 41.0     | 13.4   | 14.8                | 8.2          | 28.7                            | 1.5          | 0.5                 | 0                             | 0                             |
| Malaysia  | 7.8            | 33.5     | 9.0    | 13.4                | 85.9         | 56.0                            | 19.8         | 1.3                 | 0.3                           | 0.5                           |
| Indonesia | 1.2            | 32.6     | 2.1    | 5.3                 | 1472         | 84.0                            | 70.0         | 16.7                | 0                             | 15.6                          |
| Thailand  | 8.2            | 40.8     | 13.0   | 15.5                | 182.5        | 249                             | 18.0         | 8.4                 | 0                             | 0.7                           |
| Singapore | 7.4            | 41.2     | 9.7    | 15.1                | 9.4          | 50.8                            | 29           | 0.5                 | 0                             | 0                             |
| Philippines | 5.2           | 27.0     | 12.3   | 15.3                | 1476         | 108.4                           | 105.0        | 16.8                | 0.3                           | 7.7                           |
| Kuwait    | 8.3            | 31.0     | 17.0   | 12.5                | 21.0         | 30.2                            | 7.5          | 0.4                 | 0.1                           | 0                             |
| Pakistan  | 96             | 299      | 8.5    | 181                 | 240.6        | 126.8                           | 73.7         | 57.7                | 2.3                           | 0                             |
| Iran      | 26             | 176      | 11.1   | 76                  | 30.5         | 174                             | 49           | 14.8                | 0                             | 0.3                           |
| Lebanon   | 47             | 25.4     | 14.4   | 15.4                | 34.3         | 28.3                            | 1.6          | 8.0                 | 0.1                           | 0.1                           |
| Oman      | 47             | 23.8     | 8.9    | 11.4                | 13.2         | 9.1                             | 2.1          | 5.6                 | 0                             | 0                             |
| Morocco   | 8.7            | 23.7     | 7.4    | 12.0                | 478          | 35.4                            | 14.0         | 20.8                | 0.1                           | 5.2                           |
| Malta     | 7.7            | 47.4     | 16.0   | 28.9                | 39           | 36.2                            | 0.4          | N/A                 | 0.1                           | 0.1                           |
| Argentina | 7.3            | 62.4     | 10.9   | 22.8                | 372          | 281                             | 2.1          | 1.0                 | 1.6                           | 0.1                           |
| Brazil    | 5.2            | 36.7     | 22.7   | 16.1                | 573          | 42.7                            | 9.7          | 9.9                 | 7.5                           | 0.1                           |
| Chile     | 8.8            | 21.0     | 10.2   | 11.7                | 213          | 31.9                            | 4.1          | 1.7                 | 0.4                           | 0.1                           |
| Paraguay  | 10.8           | 66.6     | 194    | 34.5                | 64.7         | 41.5                            | 24.1         | 11.8                | 1.4                           | 0.5                           |
| Peru      | 8.2            | 34.5     | 260    | 193                 | 99.8         | 115.6                           | 30.5         | 14.2                | 5.8                           | 1.4                           |
| Uruguay   | 7.2            | 34.5     | 19.0   | 16.0                | 185          | 178                             | 1.9          | 2.0                 | 0.1                           | 0                             |
| Mexico    | 44             | 22.2     | 6.6    | 94                  | 25.2         | 36.2                            | 4.6          | 6.1                 | 0                             | 0.1                           |
| Costa Rica| 72             | 30.9     | 13.7   | 14.6                | 36.4         | 13.5                            | 3.0          | 3.6                 | 0                             | 0.1                           |
| Panama    | 78             | 24.1     | 176    | 94                  | 43.2         | 20.2                            | 4.4          | 5.9                 | 0.3                           | 0.1                           |
| Canada    | 94             | 39.8     | 28.1   | 18.5                | 73           | 9.7                             | 0.3          | 5.0                 | 0                             | 0.1                           |
| Country        | Atopic eczema | Rhinitis | Wheeze | Rhinoconjunctivitis | ID mortality | Respiratory infections mortality | TB mortality | Diarrhoea mortality | Tropical infections mortality | Childhood infections mortality |
|----------------|---------------|----------|--------|---------------------|--------------|---------------------------------|--------------|---------------------|-------------------------------|--------------------------------|
| United States  | 8.5           | 34.6     | 21.7   | 17.9                | 16.0         | 11.3                            | 0.2          | 0.3                 | 0                             | 0.1                            |
| Barbados       | 50            | 16.4     | 11.0   | 56.8                | 19.3         | N/A                             | 1.0          | 0                   | 0.3                           |                                |
| Austria        | 5.2           | 21.6     | 11.6   | 10.4                | 2.8          | 7.1                             | 0.4          | 0                   | 0                             | 0.1                            |
| Belgium        | 6.7           | 36.4     | 12.0   | 14.5                | 7.7          | 20.2                            | 0.6          | 0.4                 | 0                             | 0.1                            |
| Estonia        | 5.7           | 21.9     | 10.8   | 5.0                 | 14.1         | 19.1                            | 5.3          | 0.1                 | 0                             | 0.1                            |
| Finland        | 15.6          | 37.1     | 16.0   | 16.7                | 4.5          | 21.9                            | 1.0          | 0.3                 | 0                             | 0.1                            |
| France         | 10.0          | 46.5     | 13.5   | 16.1                | 7.4          | 13.7                            | 1.0          | 0.5                 | 0                             | 0.1                            |
| Germany        | 6.9           | 29.0     | 13.8   | 13.4                | 7.9          | 11.0                            | 0.4          | 0.2                 | 0                             | 0.1                            |
| Greece         | 3.1           | 14.4     | 3.7    | 6.3                 | 3.5          | 14.1                            | 0.5          | 0                   | 0                             | 0.1                            |
| Italy          | 57            | 273      | 8.9    | 13.6                | 54           | 14.1                            | 0.4          | 0                   | 0                             | 0.1                            |
| Latvia         | 4.9           | 22.3     | 8.4    | 5.0                 | 276          | 12.3                            | 9.4          | 0.4                 | 0                             | 0.1                            |
| Lithuania      | 1.7           | 276      | 8.2    | 5.6                 | 13.0         | 8.8                             | 8.1          | 0.1                 | 0                             | 0.1                            |
| Poland         | 54            | 18.3     | 8.1    | 9.5                 | 59           | 12.9                            | 2.3          | 0.1                 | 0                             | 0.1                            |
| Portugal       | 44            | 21.1     | 9.5    | 7.3                 | 24.4         | 28.8                            | 2.4          | 0.1                 | 0                             | 0.1                            |
| Romania        | 6.3           | 11.5     | 3.0    | 5.2                 | 16.6         | 26.7                            | 9.0          | 1.0                 | 0                             | 0.1                            |
| Spain          | 44            | 32.1     | 10.3   | 15.0                | 10.1         | 10.7                            | 0.7          | 0.3                 | 0                             | 0.1                            |
| Sweden         | 14.5          | 23.0     | 12.9   | 11.7                | 5.3          | 11.7                            | 0.3          | 0.2                 | 0                             | 0.2                            |
| United Kingdom | 8.8           | 34.3     | 32.2   | 18.4                | 5.1          | 45.8                            | 0.5          | 0.5                 | 0                             | 0.1                            |
| Ireland        | 13.6          | 41.8     | 29.1   | 20.0                | 5.5          | 43.0                            | 0.9          | 0.1                 | 0                             | 0.1                            |
| Russia         | 4.0           | 19.7     | 7.15   | 7.0                 | 33.0         | 21.0                            | 18.4         | 0.8                 | 0                             | 0.1                            |
| Ukraine        | 53            | 20.7     | 12.9   | 11.2                | 39.8         | 11.8                            | 11.3         | 0.5                 | 0                             | 0.1                            |
| Uzbekistan     | 3.3           | 13.1     | 10.2   | 10.4                | 32.2         | 43.4                            | 22.3         | 2.0                 | 0                             | 0.3                            |
| Albania        | 0.8           | 12.7     | 2.6    | 4.0                 | 8.1          | 41.3                            | 1.0          | 0.2                 | 0.1                           | 0.1                            |
| Georgia        | 2.6           | 12.8     | 3.7    | 4.4                 | 14.8         | 16.7                            | 12.4         | 0.7                 | 0                             | 0.1                            |
| India          | 3.7           | 13.7     | 6.5    | 6.2                 | 211.3        | 129.3                           | 42.8         | 38.9                | 3.2                           | 21.5                           |
| Australia      | 97            | 37.2     | 29.4   | 19.3                | 6.0          | 7.9                             | 0.2          | 0.1                 | 0                             | 0.1                            |
| New Zealand    | 12.7          | 38.8     | 30.2   | 18.7                | 3.4          | 8.5                             | 0.4          | 0.2                 | 0                             | 0.1                            |

ID, infectious diseases; TB, tuberculosis; N/A, not available.
may lead to an increased risk of both atopic and infectious diseases. Atopic eczema is known to be associated with Th2 predominance [14, 15]. The relation between a Th2 response and increased risk of infections has been demonstrated in animal studies [16-18] as well as in humans [19, 20]. Another factor which may predispose to both atopic and infective conditions in later life could be lack of microbial exposure during early postnatal life, as suggested by the ‘hygiene hypothesis’ [21]. This may be mediated through alteration of the gut microbiota, which may predispose to atopy [22, 23] as well as to infections [24].

Alternatively, atopy may itself lead to in Th2/Th1 predominance, which in turn may predispose to an increased infection risk. Atopic disease features increased systemic Th2 responses and Th2/Th1 responses in lesional skin, but there is evidence that allergies also result in impaired innate immunity namely by Th2 polarisation [25]. Many mediator cells in atopy, including mast cells, basophils and eosinophils, are capable of shifting the balance to Th2 polarization through production of interleukin-4 (IL-4) [26, 27]. IL-4 is also thought to trigger fibronectin production by skin fibroblasts which facilitated bacterial attachment, the first step in establishing an infection [28]. Furthermore, Gros et al. [29] have reported that the enhanced Th2 immunity in patients with atopic dermatitis leads to an impairment of Th1 immune responses by altering the interferon-gamma responses of antigen presenting cells. One can speculate that the positive association between atopy and infectious disease mortality is based on the interaction between interleukins and type 1/2 cytokines. Hoffmann et al. [30] have shown that excessive types 1 and 2 cytokine responses secondary to interleukin regulatory processes in schistosomiasis increases mortality. Upregulation of the Th2 responses in atopic disease in the setting of interleukin deficiency could be one of the possible causes of increased mortality in these patients.

Respiratory infections have been reported to be more common and more severe in individuals with allergic diseases [31-33]. Our study, on the other hand, failed to show a correlation of allergic conditions with mortality from respiratory infections at country level, although there was a nonsignificant trend. This is probably
Association of atopy with infectious disease mortality

Table 3. Correlation between ISAAC phase 1 and antibiotic sensitivity for *Streptococcus pneumoniae* and *Haemophilus influenzae*

| Analysis by country & antibiotic sensitivity | Correlation (r) | p value (two-sided) |
|---------------------------------------------|-----------------|-------------------|
| Atopic eczema                               |                 |                   |
| *S. pneumoniae* to penicillin               | −0.29           | 0.240             |
| *S. pneumoniae* to erythromycin             | −0.38           | 0.110             |
| *S. pneumoniae* to doxycycline              | −0.16           | 0.520             |
| *S. pneumoniae* to cotrimoxazole            | −0.06           | 0.820             |
| *H. influenzae* to ampicillin               | 0.17            | 0.780             |
| *H. influenzae* to erythromycin             |                 |                   |
| *H. influenzae* to doxycycline              | 0.15            | 0.390             |
| *H. influenzae* to cotrimoxazole            | −0.39           | 0.500             |
| Rhinitis                                    |                 |                   |
| *S. pneumoniae* to Penicillin               | −0.51           | 0.029*            |
| *S. pneumoniae* to erythromycin             | −0.51           | 0.027*            |
| *S. pneumoniae* to doxycycline              | −0.37           | 0.140             |
| *S. pneumoniae* to cotrimoxazole            | −0.29           | 0.250             |
| *H. influenzae* to ampicillin               | −0.59           | 0.010*            |
| *H. influenzae* to erythromycin             |                 |                   |
| *H. influenzae* to doxycycline              | −0.08           | 0.790             |
| *H. influenzae* to cotrimoxazole            | 0.033           | 0.890             |
| Rhinoconjunctivitis                         |                 |                   |
| *S. pneumoniae* to Penicillin               | −0.41           | 0.100             |
| *S. pneumoniae* to erythromycin             | −0.34           | 0.180             |
| *S. pneumoniae* to doxycycline              | −0.17           | 0.520             |
| *S. pneumoniae* to cotrimoxazole            | −0.24           | 0.350             |
| *H. influenzae* to ampicillin               | −0.51           | 0.030*            |
| *H. influenzae* to erythromycin             |                 |                   |
| *H. influenzae* to doxycycline              | 0.1             | 0.710             |
| *H. influenzae* to cotrimoxazole            | −0.16           | 0.530             |
| Wheezing                                    |                 |                   |
| *S. pneumoniae* to Penicillin               | −0.16           | 0.530             |
| *S. pneumoniae* to erythromycin             | 0.16            | 0.520             |
| *S. pneumoniae* to doxycycline              | 0.35            | 0.150             |
| *S. pneumoniae* to cotrimoxazole            | 0.03            | 0.910             |
| *H. influenzae* to ampicillin               | −0.24           | 0.350             |
| *H. influenzae* to erythromycin             |                 |                   |
| *H. influenzae* to doxycycline              | −0.06           | 0.800             |
| *H. influenzae* to cotrimoxazole            | −0.04           | 0.880             |

ISAAC, International Study of Asthma and Allergies in Childhood study.

*p* value of <0.05 was considered as statistically significant.

due to the fact that such respiratory conditions are usually nonfatal and we studied mortality data rather than incidence of infections. It is therefore probable that total infectious disease mortality in a given country is a better marker of its total infective burden than is mortality from respiratory infections. We also found no association between mortality from tuberculosis and prevalence of atopic eczema. This may be due to the factors other than Th2/Th1 predominance being more important in determining tuberculosis mortality, such as coinfection with human immunodeficiency virus.

In contrast to atopic eczema, we found no significant correlation between prevalence of wheezing, rhinoconjunctivitis and rhinitis and infectious disease mortality. This suggests that there are important differences between the pathophysiology of eczema and that of other allergic conditions. These may include the role of staphylococcal superantigen, which has been shown to facilitate epithelial presentation of allergen to Th2 cells [34] and the role of other infective agents in eczema [35].

We also explored the relationship between the same atopic conditions and antibiotic susceptibility of *S. pneumoniae* and *H. influenzae*. In our study we found a negative correlation between rhinitis and susceptibility of *S. pneumoniae* to penicillin and erythromycin and of *H. influenzae* to ampicillin. There was also a negative correlation between rhinoconjunctivitis and susceptibility of *H. influenzae* to ampicillin (Fig. 3).

Antibiotic susceptibility is known to be inversely related with local use and abuse of antibiotics. Antibiotic susceptibility depends not only on personal use but also usage in the community as whole, including use in agriculture. It is therefore a strong marker of antibiotic exposure of the community. Our data therefore suggest that increased antibiotic use in a community may be associated with increased risk of atopic disease. Various mechanisms may be implicated. Firstly, increased antibiotic use may decrease bacterial exposure during early postnatal life. Bacterial exposure during these critical periods in early life may help in protecting against atopic disease by decreasing Th1 response [36]. Interestingly, Gram-positive bacteria seem to be more important in stimulating this response [37]. Antibiotic use can also cause long-lasting effects on the constitution and diversity of gut microbiota [38, 39], which have been linked to increased risk of atopic disease [40-42]. Antibiotic use can also affect skin microbiota, which has been implicated in atopic eczema [43].
Strengths and limitations

This ecological study is based on international research projects involving large numbers of patients of the same age groups. Countries participating in all three studies were utilised for this analysis. The use of age standardized WHO mortality rates and the ISAAC 13- to 14-year-old cohort prevalence rates makes interpretation of results much more accurate and valid.

The main limitation of this study is that the data was obtained from three different research projects which were carried out at different times. However data from the ISAAC study shows there has very little change in prevalence of current wheeze, atopic eczema or rhinoconjunctivitis over time [44, 45]. Therefore, the time factor is unlikely to have had a major impact on our results.

One important limitation of this ecological study is the presence of systematic differences that might have occurred during disease.
The association of atopy with infectious disease mortality which is an important skin pathogen Staphylococcus aureus which is an important skin pathogen associated with atopic eczema, but this data was not available.

The reliability of our findings depends on the reliability of the original data. However all the studies utilised very robust methodology. We also appreciate that we studied only organisms associated with respiratory infections and did not include Staphylococcus aureus which is an important skin pathogen associated with atopic eczema, but this data was not available.

**Conclusion**

We found a significant positive correlation between the prevalence of atopic eczema and mortality from infectious diseases. A high prevalence of eczema could be a marker of environmental and/or genetic predisposition of the population to an enhanced Th2 response, which may lead to an increased infection risk (and hence higher mortality from infectious diseases). One possible environmental factor predisposing to a Th2/Th1 response could be lack of microbial exposure during critical periods in early postnatal life.

We also found a negative correlation between rhinitis and susceptibility of S. pneumoniae to penicillin and erythromycin and of H. influenzae to ampicillin. The overprescription of antibiotics in these allergic conditions could have a direct effect on the susceptibilities of organisms to commonly used antimicrobials. More work is needed to confirm the role of interleukins in infectious disease mortality secondary to atopic disease. Furthermore an in-depth analysis is needed looking at the way antibiotics are prescribed for atopic disease both at a country level and at a global level.

**REFERENCES**

1. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112(6 Suppl):S118-27.
2. Williams H, Robertson C, Stewart A, Att-Khaled N, Anawbani G, Anderson R, Asher I, Beasley R, Bjorksten B, Burr M, Clayton T, Crane J, Ellwood P, Keil U, Lai C, Mallol J, Martinez F, Mitchell E, Montefort S, Pearce N, Shah J, Sibbald R, Strachan D, von Mutius E, Weiland SK. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103(1 Pt 1):125-38.
3. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol 2011;131:67-73.
4. Trepka MJ, Heinrich J, Wichmann HE. The epidemiology of atopic diseases in Germany: an east-west comparison. Rev Environ Health 1996;11:119-31.
5. Fsadni P, Fsadni C, Fava S, Montefort S. Correlation of worldwide incidence of type 1 diabetes (DiaMond) with prevalence of asthma and atopic eczema (ISAAC). Clin Respir J 2012;6:18-25.
6. Gale EA. A missing link in the hygiene hypothesis? Diabetologia 2002;45:588-94.
7. Strachan DP. Family size, infection and atopy: the first decade of the “hygiene hypothesis”. Thorax 2000;55 Suppl 1:S2-10.
8. Abela AG, Fava S. Association of incidence of type 1 diabetes with mortality from infectious disease and with antibiotic susceptibility at a country level. Acta Diabetol 2013;50:859-65.
9. International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee [Internet]. Auckland (NZ): ISAAC; 2010 [cited 2014 Jan 30]. Available from: http://isaac.auckland.ac.nz.
10. Mathers CD, Bernard C, Iburg K, Inoue M, Ma Fat D, Shibuya K, Stein C, Tomijima N, Xu H. Global burden of disease in 2002: data sources, methods and results. Global programme on evidence for health policy discussion paper No. 54 [Internet]. Geneva: World Health Organization; c2015 [cited 2014 Jan 30]. Available from: http://www.who.int/healthinfo/paper54.pdf.
11. World Health Organization. The World Health Report 2004: changing history [Internet]. Geneva: World Health Organization; c2015 [cited 2014 Jan 30]. Available from: http://www.who.int/whr/2004/en/.
12. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46.
13. Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol 2009;129:543-52.
14. Akdis M, Trautmann A, Klunker S, Daigle I, Kucukcezer UC, Deglmann W, Disch R, Blaser K, Akdis CA. T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 2003;17:1026-35.
15. Akkoc I, de Koning PJ, Ruckert B, Barlan I, Akdis M, Akdis CA. Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(h)2 predominance in atopic diseases. J Allergy Clin Immunol 2008;121:652-658.e1.
16. Ehren JM, Roth J, Roebrock K, Varga G, Domschke W, Newberry R,
Sorg C, Muller-Tidow C, Sunderkotter C, Kucharzik T, Spahn TW. The absence of cutaneous lymph nodes results in a Th2 response and increased susceptibility to Leishmania major infection in mice. Infect Immun 2008;76:4241-50.

17. Fernandez-Cabezudo MJ, Ali SA, Ullah A, Hasan MY, Kosanovic M, Fahim MA, Adem A, al-Ramadi BK. Pronounced susceptibility to infection by Salmonella enterica serovar Typhimurium in mice chronically exposed to lead correlates with a shift to Th2-type immune responses. Toxicol Appl Pharmacol 2007;218:215-26.

18. Arendse B, Van Snick J, Bormbacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005;174:2205-11.

19. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, Stanciu LA, Gnesini G, Pastore A, Spanevello A, Morelli P, Johnston SL, Caramori G, Papi A. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy 2015 Apr 8 [Epub]. http://dx.doi.org/10.1111/all.12627.

20. Bhattacharya D, Dwivedi VP, Kumar S, Reddy MC, Van Kaer L, Moodley P, Das G. Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem 2014;289:33404-11.

21. Schmitz R, Atzpodenien K, Schlaut K. Prevalence and risk factors of atopic diseases in German children and adolescents. Pediatr Allergy Immunol 2012;23:716-23.

22. Drago L, Toscano M, De Vecchi E, Piconi S, Iemoli E. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin Gastroenterol 2012;46 Suppl:S56-63.

23. Iemoli E, Trabattoni D, Parissoto S, Borgonovo L, Toscano M, Rizzardini G, Clerici M, Ricci E, Fusi A, De Vecchi E, Piconi S, Drago L. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol 2012;46 Suppl:S33-40.

24. Endt K, Stecher B, Chaffron S, Slack E, Tchitchek N, Benecke A, Van Meele L, Sirard JC, Mueller AJ, Heikinwalder M, Macpherson AJ, Strugnell R, von Mering C, Hardt WD. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog 2010;6:e1001097.

25. Mrabet-Dahbi S, Maurer M. Does allergy impair innate immunity? Leads and lessons from atopic dermatitis. Allergy 2010;65:1351-6.

26. Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 2009;129:1878-91.

27. Simon D, Kozlovsky E, Simon H. Natural killer T cells expressing IFN-gamma and IL-4 in lesional skin of atopic eczema. Allergy 2009;64:1681-4.

28. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-85.

29. Gros E, Petzold S, Maintz L, Bieber T, Novak N. Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol 2011;128:1015-21.

30. HoffmannKF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 2000;164:6406-16.

31. Silverberg JJ, Silverberg NB. Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study. J Allergy Clin Immunol 2014;133:1041-7.

32. Ciprandi G, Tosca MA, Fasce L. Allergic children have more numerous and severe respiratory infections than non-allergic children. Pediatr Allergy Immunol 2006;17:389-91.

33. Cirillo I, Marseglia G, Klersy C, Ciprandi G. Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects. Allergy 2007;62:1087-90.

34. Ardern-Jones MR, Black AP, Bateman EA, Ogg GS. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci U S A 2007;104:5557-62.

35. Hussain I, Smith J. Evidence for the transmissibility of atopity: hypothesis. Chest 2003;124:1968-74.

36. Baboonian C, Venables PJ, Williams DG, Williams RO, Maini RN. Cross reaction of antibodies to a glycine/alanine repeat sequence of Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin. Ann Rheum Dis 1991;50:772-5.

37. Lappalainen MH, Hyvarinen A, Hirvonen MR, Rintala H, Roivainen J, Renz H, Pflefferle PI, Nevalainen A, Roponen M, Pekkanen J. High indoor microbial levels are associated with reduced Th1 cytokine secretion capacity in infancy. Int Arch Allergy Immunol 2012;159:194-203.

38. Tanaka S, Kobayashi T, Songiinda P, Tateyama A, Tsushouchi M, Kiyohara C, Shirakawa T, Sonomoto K, Nakayama J. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunol Med Microbiol 2009;56:80-7.

39. Greenwood C, Morrow AL, Lagom aromatico AJ, Altaye M, Taft DH, Yu Z, Newburg DS, Ward DV, Schibler KR. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr 2014;165:23-9.

40. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol 2012;129:434-40, 440.e1-2.

41. Forno E, Onderdonk AB, McCracken J, Litioniuja AA, Laskey D, Delaney

http://dx.doi.org/10.5415/apallergy.2015.5.3.145

apallergy.org
ML, Dubois AM, Gold DR, Ryan LM, Weiss ST, Celedon JC. Diversity of the gut microbiota and eczema in early life. Clin Mol Allergy 2008;6:11.

42. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007;56:661-7.

43. Salava A, Lauerma A. Role of the skin microbiome in atopic dermatitis. Clin Transl Allergy 2014;4:33.

44. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C; ISAAC Phase Three Study Group. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007;62:758-66.

45. Asher MI, Stewart AW, Wong G, Strachan DP, Garcia-Marcos L, Anderson HR; ISAAC Phase Three Study Group. Changes over time in the relationship between symptoms of asthma, rhinoconjunctivitis and eczema: a global perspective from the International Study of Asthma and Allergies in Childhood (ISAAC). Allergol Immunopathol (Madr) 2012;40:267-74.